CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease  Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults1Based upon positive SENSCIS ® trial results nintedanib was approved as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with SSc-ILD2Nintedanib is already approved in more than 70 countries for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news